Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say - Reuters

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNRXcwd2ZTOXFZNXBqRlU5ZERTQkVXYW1BZDFpZFpNOXVEdEk1V3pDUEdpa0FadURxcGYtMVNjRHRBSkxoWDdxcWtBcERNVUdaYkU1d1lCWlFMT1dkX3pHOVp1dnUtSko3aERhaDh5UElCd0RlcWpOQmIwNVdHbmJiUWQyZjNOQlY3QUhRWHV1N3h1QnFNdUhVemo2UkltZF9NeklhWjRmNWVuZ2ZfUEJ2Z2dmVnR3Z29N?oc=5" target="_blank">Indian drugmaker Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Dr Reddy's Laboratories plans to launch its generic semaglutide injection, potentially named Obeda, in India by March 2026, following the patent expiry of semaglutide. The company aims to price it competitively, potentially up to 60% below the branded product.

Dr Reddy's Laboratories has applied to trademark the brand name 'Obeda' for its upcoming generic version of semaglutide, the active ingredient in Novo Nordisk's Ozempic. The launch is anticipated in March 2026, coinciding with the patent expiry of semaglutide in India.